Clomid: How It Works and Why It's Used Less for PCOS Now

You may have been handed a prescription for clomid by a general gynecologist before you ever saw a fertility specialist, or you may be the friend in your group who got the older drug while someone else got letrozole. This post walks through what clomid is doing inside the ovary, why it ran the field for half a century, and why for PCOS specifically the prescribing pattern has shifted since 2014. The aim is a fair, honest look at the drug that built modern ovulation induction, not a takedown.

When I sit with someone starting their first medicated cycle, I want them to understand that clomid is not a bad drug. It is a useful drug that has helped a very large number of people conceive across more than fifty years of clinical use. What has changed, and what the rest of this post is really about, is that for the specific population of people with polycystic ovary syndrome (PCOS), the evidence now points to a different first choice. That shift was settled in a single landmark trial published in 2014, and the practice has caught up steadily since.

What is clomid and how does it work?

Clomid is the brand name for clomiphene citrate, an oral medication taken as a short course of pills at the start of the menstrual cycle. It belongs to a class of drugs called selective estrogen receptor modulators, or SERMs. The same class includes tamoxifen, used in breast cancer care, and the two drugs share a molecular ancestry.

The mechanism is indirect and worth understanding because it explains both the strengths and the weaknesses. Clomiphene binds to estrogen receptors in the hypothalamus, the part of the brain that monitors circulating estrogen levels. When those receptors are blocked, the hypothalamus reads the situation as if estrogen is low, even when it is not. It responds by signalling the pituitary gland to release more gonadotropin-releasing hormone, which in turn drives a stronger pulse of follicle-stimulating hormone (FSH) and luteinizing hormone (LH).⁴ That stronger FSH pulse is what recruits a follicle and pushes ovulation.

The trouble is that clomiphene does not block estrogen receptors only at the hypothalamus. It blocks them throughout the body, including at the endometrium (the uterine lining) and at the cervix. It also has a half-life of roughly five to seven days, which means the drug is still active in your bloodstream during the fertile window, when the lining and cervical mucus are supposed to be responding to rising estrogen. We will come back to this, because it is the single most important mechanistic reason the drug has lost ground for PCOS specifically.

Why was clomid first-line for decades?

Clomiphene was approved for use in ovulation induction in 1967. For most of the time since then, it has been the default oral drug for people who do not ovulate reliably, including those with PCOS. There are good reasons it earned that position.

The drug is cheap. A standard five-day course of 50mg tablets is inexpensive in nearly every market, often a fraction of the cost of even the older injectable options. It is oral, so there are no needles, no refrigeration, and no clinic visit required to administer the dose. It is familiar. Every gynecologist trained in the past forty years has prescribed it, and that means it can be initiated outside specialist fertility clinics in settings where access to a reproductive endocrinologist (RE) is limited.

The effectiveness is also genuine. Across pooled data, clomid produces ovulation in roughly seventy percent of treated cycles in people with anovulatory infertility, and a per-ovulatory-cycle pregnancy rate of approximately fifteen percent in the absence of other infertility factors.³ Cumulative pregnancy rates over three to six cycles sit in the range of thirty to forty percent for appropriately selected patients. Those are not small numbers, and a generation of fertility care, including the original protocols for ovulation timing, follicle monitoring, and trigger shots, was built around them.

For someone with mild ovulatory dysfunction, intact tubes, and a partner with normal sperm parameters, clomid still works. The question is no longer whether clomid produces ovulation. It is whether, in PCOS specifically, a different drug produces it more reliably and with a better downstream cycle.

What did the PALO trial change for PCOS?

In 2014, Richard Legro and colleagues at the Reproductive Medicine Network published the Pregnancy in Polycystic Ovary Syndrome (PALO) trial in the New England Journal of Medicine. The trial enrolled 750 women with PCOS and infertility, and randomly assigned them to receive either letrozole or clomiphene for up to five treatment cycles.¹ The primary outcome was live birth.

The headline numbers were these. The cumulative live-birth rate was 27.5% on letrozole versus 19.1% on clomid. The ovulation rate per cycle was 61.7% on letrozole versus 48.3% on clomid. The multiple-pregnancy rate slightly favored letrozole as well, with a lower twin rate. Endometrial thickness on the day of trigger was better preserved with letrozole. The signal was consistent across subgroups and across all five cycles studied.

An eight-percentage-point absolute gap in live birth, in a population the size of PALO, is large for a fertility trial. It is the difference between roughly one in five and roughly one in four people taking a five-cycle course of treatment going home with a baby. That is the kind of effect size that changes guidelines, and it did. The American Society for Reproductive Medicine (ASRM), the European Society of Human Reproduction and Embryology (ESHRE), the National Institute for Health and Care Excellence (NICE), and the 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS all now position letrozole as the first-line ovulation induction agent in PCOS, in preference to clomiphene.⁶

A 2018 Cochrane review of aromatase inhibitors for PCOS reached the same conclusion, with no signal of harm.³ The position is not based on one trial alone. PALO is the anchor, and the systematic reviews and registry data that followed have not shifted the picture.

Why does clomid cause a thinner uterine lining?

This is the mechanistic reason letrozole pulls ahead, and it is worth spending a paragraph on because it shows up in real cycle data.

Because clomiphene blocks estrogen receptors throughout the body, and because the drug is still circulating during the proliferative phase of the cycle, the endometrium does not respond normally to the rising estrogen that follows follicle recruitment. The lining is supposed to thicken from roughly three to four millimeters at the start of the cycle to seven to twelve millimeters by the day of trigger. In approximately fifteen percent of clomid cycles, the lining fails to cross seven millimeters by trigger day.³ A lining that thin is associated with lower implantation rates, even when ovulation looks perfect on every other metric.

Letrozole, in contrast, is an enzyme inhibitor rather than a receptor blocker. It briefly lowers the body's estrogen production, the brain responds by releasing more FSH, and then the drug clears the body. Letrozole has a half-life of about forty-five hours, which means a five-day course taken on days three to seven is essentially gone by the time ovulation happens. The lining is not exposed to the drug during the window when implantation will be tested. That is the difference, in one sentence.

The same logic applies to cervical mucus. Clomid's anti-estrogenic effect at the cervix reduces the volume and stretchiness of fertile mucus, which can make sperm transit through the cervix less efficient. This is why clomid plus intrauterine insemination (IUI) is sometimes used to bypass the mucus problem rather than rely on timed intercourse. Letrozole does not produce this effect to the same degree.

What is the standard clomid protocol?

If your gynecologist or RE has prescribed clomid, the protocol is likely close to this. There is some variation between clinics, and your team may adjust based on your specific history.

1. Day 1: First day of a true period (not spotting). If you do not menstruate spontaneously, a short course of progesterone is sometimes given to induce a withdrawal bleed before starting.
2. Days 3 to 7, or days 5 to 9: Take 50mg of clomid once daily, for five days. The evidence does not strongly favor one window over the other.
3. Day 11 to 14: Some clinics monitor with a transvaginal ultrasound scan to check follicle size and endometrial lining. Others, in low-risk patients, run unmonitored cycles.
4. Ovulation trigger or LH surge tracking: If monitored, some clinics give a single hCG trigger when a follicle reaches 18 to 22mm. Otherwise, the cycle relies on a positive ovulation predictor kit (OPK) to time intercourse or IUI.
5. Timed intercourse or IUI: Around 24 to 36 hours after the trigger, or after a positive OPK.
6. Day 21, or seven days post-ovulation: Progesterone blood test to confirm ovulation actually occurred. A level above 10 ng/mL is generally reassuring; above 3 ng/mL is the threshold for "ovulation happened."

If you do not ovulate on 50mg, the standard escalation is 100mg in the next cycle, then 150mg if needed. Most protocols cap dosing at 150mg per cycle.⁴ The clinical convention is to discontinue clomid after three to six ovulatory cycles without pregnancy, because the cumulative pregnancy gain per additional cycle drops sharply after that. I cover this cycle-rule logic in detail in a dedicated post.

When is clomid still the right choice?

I do not want to leave the impression that clomid is obsolete, because it is not. There are scenarios where I, and many REs, will reach for clomid first or stay with it through a cycle.

Prior clomid responders: If you conceived on clomid before, and you are back trying for a second baby, the cleanest signal in your data is your own history. Switching drugs for the sake of switching is rarely the right move. The same is true if you ovulated reliably and pregnancy was lost for unrelated reasons.

Unexplained infertility: The data in this group is more mixed than in PCOS. The AMIGOS trial (Diamond et al. 2015) compared letrozole, gonadotropins, and clomid in couples with unexplained infertility and showed the lowest live-birth rate with letrozole, not clomid.² The picture in unexplained infertility is not a simple "letrozole wins." For PCOS specifically, the evidence is one-directional. For unexplained, your RE will weigh the trade-offs differently.

Access-constrained settings: Letrozole's use for ovulation induction is off-label in the United States and several other countries, which can affect insurance coverage and pharmacy availability. In settings where letrozole is harder to source or where the cost differential is meaningful, clomid remains the practical choice. Globally, in many regions, clomid is still the most prescribed ovulation induction drug, and that is a defensible position when access to the alternative is genuinely limited.

Specific clinical scenarios: Some REs use clomid in particular protocols, including some luteal phase support regimens and male-factor cases where clomid is used in the male partner to raise testosterone and improve sperm parameters. Those are separate uses, outside the scope of this post.

What I would not do, in 2026, is start a new cycle of clomid for a PCOS patient who has access to letrozole, in the absence of one of the reasons above. That is the practice change PALO produced, and the 2023 PCOS guideline backs it explicitly.⁶

What are the side effects of clomid?

Most clomid side effects are tolerable and short-lived, though they have a longer arc than letrozole symptoms because the drug stays in the system through ovulation. The common ones include hot flashes (roughly ten to twenty percent of cycles), mood changes and irritability, headache, breast tenderness, and bloating. Most resolve once the drug clears. I cover the full list, and the practical adjustments that make the dosing window easier, in a dedicated side-effects post.

One symptom genuinely warrants a same-day call to your clinic: any visual disturbance. Blurred vision, light sensitivity, flashing lights, or new floaters are uncommon (around one to two percent of cycles) but are a known clomid effect and a reason to stop dosing and be evaluated before any further clomid is prescribed.⁴ This, along with the rest of the clomid side-effect list, is the standout safety point most patients should know before starting.

The multiple-pregnancy rate on clomid is approximately eight to ten percent, almost all twins, with a small additional triplet risk. That is meaningfully higher than letrozole's three to four percent twin rate. For some couples, that is acceptable. For others, particularly with PCOS and a higher antral follicle count, the difference matters when picking between the two drugs.

On long-term cancer risk, the older concern about clomid and ovarian cancer has not been borne out by the larger follow-up studies. The 1994 Rossing analysis, which raised the initial signal, has been followed by larger cohorts that have not confirmed an increased risk at fertility doses and exposure durations.

What should I ask my doctor about clomid?

If you are about to start clomid, or you are reading this on cycle two and trying to figure out whether to keep going, these are the conversations worth having.

• Why clomid for me specifically, given that letrozole is the current first-line for PCOS.
• Are we monitoring lining and follicles, or running an unmonitored cycle.
• What is the plan if I do not ovulate on 50mg.
• How many cycles before we change drug or step up to IUI.
• Should I be on metformin alongside this, given my insulin profile.

If you have a partner in this with you, the cycle before the cycle is the calmest moment to align on what "stepping up" would mean later. Those decisions are easier to think through before the disappointment of a negative test, not after.

What's next

• If your first clomid cycle ends in a positive test: the two-week wait
• If you are weighing the two drugs side by side: clomid vs letrozole, which one and why
• If you are on cycle three or four without success: when clomid stops working, the 3 to 6 cycle rule
• If your RE has just suggested switching: switching from clomid to letrozole, what changes
• If this cycle failed and you need support before the next decision: when things don't go to plan

Related in this cluster

• Clomid Side Effects: What to Expect

Sources

1. Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. New England Journal of Medicine 2014;371(2):119-129. https://www.nejm.org/doi/full/10.1056/NEJMoa1313517
2. Diamond MP, Legro RS, Coutifaris C, et al. Letrozole, gonadotropin, or clomiphene for unexplained infertility. New England Journal of Medicine 2015;373(13):1230-1240. https://www.nejm.org/doi/full/10.1056/NEJMoa1414827
3. Brown J, Farquhar C. Clomiphene and other antioestrogens for ovulation induction in polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2016;(12):CD002249. https://doi.org/10.1002/14651858.CD002249.pub5
4. Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. Fertility and Sterility 2013;100(2):341-348. https://www.asrm.org/practice-guidance/practice-committee-documents/
5. Kar S. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: A prospective randomized trial. Journal of Human Reproductive Sciences 2012;5(3):262-265. https://doi.org/10.4103/0974-1208.106338
6. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility 2023;120(4):767-793. https://doi.org/10.1016/j.fertnstert.2023.07.025